Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Postboks 1171 Blindern, 0318, Oslo, Norway.
Acta Neurochir (Wien). 2023 Oct;165(10):3003-3010. doi: 10.1007/s00701-023-05772-7. Epub 2023 Sep 4.
Sustained cure of acromegaly can only be achieved by surgery. Most growth hormone (GH) secreting pituitary adenomas are macroadenomas (≥ 10 mm) at diagnosis, with reported surgical cure rates of approximately 50%. Long-term data on disease control rates after surgery are limited. Our aim was to estimate short- and long-term rates of biochemical control after pituitary surgery in acromegaly and identify predictive factors.
Patients operated for GH-secreting pituitary adenomas between 2005-2020 were included from the local pituitary registry (n = 178). Disease activity and treatment data were recorded at one-year (short-term) and five-year (long-term) postoperative follow-up. Biochemical control was defined as insulin-like growth factor 1 (IGF-1) ≤ 1.2 × upper limit of normal value. Multivariate regression models were used to identify factors potentially predicting biochemical control.
A total of 178 patients with acromegaly (median age at diagnosis 49 (IQR: 38-59) years, 46% women) were operated for a pituitary adenoma. Biochemical control was achieved by surgery in 53% at short-term and 41% at long-term follow-up, without additional treatment for acromegaly. Biochemical control rates by surgery were of same magnitude in paired samples (45% vs. 41%, p = 0.213) for short- and long-term follow-up, respectively. At short-term, 62% of patients with microadenomas and 51% with macroadenomas, achieved biochemical control. At long-term, the biochemical control rate was 58% for microadenomas and 37% for macroadenomas (p = 0.058). With adjunctive treatment, 82% achieved biochemical control at long-term. Baseline IGF-1 levels significantly predicted biochemical control by surgery at short-term (OR: 0.98 (95% CI: 0.96-0.99), p = 0.011), but not at long-term (OR: 0.76 (95% CI: 0.57-1.00), p = 0.053).
In unselected patients with acromegaly, the long-term biochemical control rate remains modest. Our findings indicate a need to identify patients at an earlier stage and improve therapeutic methods and surgical outcomes.
肢端肥大症的持续治愈只能通过手术实现。大多数生长激素(GH)分泌性垂体腺瘤在诊断时即为大腺瘤(≥10mm),报告的手术治愈率约为 50%。关于手术后疾病控制率的长期数据有限。我们的目的是评估肢端肥大症患者手术后短期和长期的生化控制率,并确定预测因素。
从当地垂体登记处(n=178)中纳入 2005 年至 2020 年间因 GH 分泌性垂体腺瘤而接受手术的患者。在术后一年(短期)和五年(长期)随访时记录疾病活动和治疗数据。生化控制定义为胰岛素样生长因子 1(IGF-1)≤1.2×正常上限值。使用多变量回归模型来确定可能预测生化控制的因素。
共纳入 178 例肢端肥大症患者(诊断时的中位年龄为 49(IQR:38-59)岁,46%为女性),因垂体腺瘤接受手术。手术在短期随访时实现了 53%的生化控制,在长期随访时实现了 41%的生化控制,无需额外治疗肢端肥大症。短期和长期随访时,手术的生化控制率分别为 45%和 41%,差异无统计学意义(p=0.213)。短期时,62%的微腺瘤患者和 51%的大腺瘤患者实现了生化控制。长期时,微腺瘤的生化控制率为 58%,大腺瘤为 37%(p=0.058)。附加治疗后,82%的患者实现了生化控制。基线 IGF-1 水平显著预测了短期随访时的手术生化控制(OR:0.98(95%CI:0.96-0.99),p=0.011),但不预测长期随访时的生化控制(OR:0.76(95%CI:0.57-1.00),p=0.053)。
在未选择的肢端肥大症患者中,长期生化控制率仍然较低。我们的研究结果表明,需要更早地识别患者,并改善治疗方法和手术结果。